LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS)
("Compass"), a biotechnology company dedicated to accelerating patient access to
evidence-based innovation in mental health, and Journey Clinical, a leading
psychedelic-assisted psychotherapy platform with the largest network of licensed
therapists focused on psychedelics in the US, today announced they have entered
into a research collaboration agreement to inform the development of a scalable
and practical delivery and healthcare provider training model for COMP360
psilocybin treatment, if approved for treatment-resistant depression (TRD).
The first phase of the collaboration comprises an in-depth information exchange
on the COMP360 psilocybin treatment delivery model. Together, Compass and
Journey Clinical will work to better understand the patient care experience,
depression patient pathways and care reimbursement processes, and explore
innovative care pathways for TRD patients, should COMP360 psilocybin treatment
be approved. They will conduct research into therapist training, support, and
education, and exchange information on treatment settings for psychedelic
therapies.
Journey Clinical has built the necessary infrastructure to support broad access
to new psychedelic treatments for mental health conditions, if and when
approved. Their collaborative care model connects a dedicated medical team,
licensed psychotherapists, and patients, supporting the delivery of psychedelic
treatments responsibly and at scale, starting with ketamine-assisted
psychotherapy. They have a network of over 2,000 therapists, an in-house model
of therapist peer support and mentorship, and are partnered with leading
therapist training providers.
"We are thrilled to be a research collaboration partner for Compass and to
contribute towards how COMP360 psilocybin treatment may be delivered to patients
across the US, if it receives regulatory approval," said Jonathan Sabbagh, co-
founder and CEO of Journey Clinical. "This collaboration with Compass is closely
aligned with Journey Clinical's aim to support the millions of people in the US
living with mental illness to access psychedelic treatments safely and
effectively."
Compass has previously announced research collaboration agreements with
Greenbrook TMS, a leading provider of interventional psychiatric treatments such
as transcranial magnetic stimulation, and Hackensack Meridian Health, a leading
not-for-profit health care organization and the largest, most comprehensive and
truly integrated network in New Jersey, addressing the full continuum of care
for people living with TRD.
"Compass is forming a comprehensive and diverse network of research
collaborations to inform how COMP360 psilocybin treatment can be best integrated
into the US health system," said Kabir Nath, CEO of Compass Pathways. "As a
leader in bringing psychedelic treatments to patients in the US safely,
responsibly, and at scale, Journey Clinical will be a valuable collaboration
partner for Compass. Together, we will further refine our understanding of how
COMP360 psilocybin treatment could be delivered to patients in the future."
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to
accelerating patient access to evidence-based innovation in mental health. Our
focus is on improving the lives of those who are suffering with mental health
challenges and who are not helped by current treatments. We are pioneering the
development of a new model of psilocybin treatment, in which our proprietary
formulation of synthetic psilocybin, COMP360, is administered in conjunction
with psychological support. COMP360 has been designated a Breakthrough Therapy
by the U.S. Food and Drug Administration (FDA) and has received Innovative
Licensing and Access Pathway (ILAP) designation in the UK for treatment-
resistant depression (TRD).
We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in
TRD, the largest randomized, controlled, double-blind psilocybin treatment
clinical program ever conducted. Previously, we completed a phase 2b study with
top line data showing a statistically significant (pÂ